Navigation Links
Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care

including several European countries and the USA. The compound is not currently approved in the United States.

The most common adverse events reported in ACTEMRA(TM) global clinical studies are upper respiratory tract infections, headache, nasopharyngitis and hypertension. As with other biological disease modifying anti-rheumatic drugs (DMARDs), serious infections have been reported in some patients treated with ACTEMRA(TM).

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or www.roche.us.

    (1) ACR20, ACR50 and ACR70 represent the percentage of reduction (20%, 50%

        or 70%) in certain RA symptoms and measures the number of tender

        and swollen joints, pain, patient's and physician's global assessments

        and certain laboratory markers. An ACR70 response is considered

        exceptional and represents a significant improvement in a patient's

        condition.

    (2) The Disease Activity Score (DAS)28 is a combined index that measures

        disease activity in patients with RA. It combin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
2. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
3. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
6. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
7. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
8. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
9. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
10. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
(Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... VIEW, Calif., Feb. 23, 2011 Omnicell, Inc ... of medication management systems to healthcare facilities, today announced ... 100 healthcare executives were polled to identify trends in ... purchasing decisions. The survey found that the majority of ...
... Biomatrica, Inc., a leader in room temperature biostability ... In-Q-Tel (IQT). IQT is the independent, strategic investment ... the mission of the U.S. Intelligence Community. ... has pioneered recent innovations in ambient storage of ...
Cached Medicine Technology:75 Percent of Hospital IT Leaders View Interoperability Between Vendor Systems as Critical to Operational Effectiveness in Healthcare Settings 2Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
(Date:3/1/2015)... Comparing a new source of vehicle ... Quotes Pros portal this year. A broad range of ... that are being supplied through the finder at ... prices available for each policy is now provided in ... user will first be asked to present their unique ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... 01, 2015 Indiana Fiber Network, ... Provider, announces NewWays Networking, LLC (NewWays) selected IFN ... with IFN, NewWays is well positioned to scale ... for Internet bandwidth in rural parts of Indiana,” ... to Cory Childs IFN Enterprise Sales Manager, IFN ...
(Date:3/1/2015)... California (PRWEB) March 01, 2015 Theme ... a new transition pack for Final Cut ... add accordion style transitions to any FCPX editors project.” ... given our users the tools needed to easily drag ... , The user gets many different controls over the ...
(Date:2/28/2015)... February 28, 2015 In recent years Medical ... of practicing physicians as a way for them to expand ... regarding Cannabis as medicine. Since the FDA still lists Cannabis ... resources available to licensed physicians that can help guide ... Dr. Deborah Malka in Santa Cruz, CA is a ...
Breaking Medicine News(10 mins):Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2
... in Canada,s north, Canada would benefit from enhanced relationships ... CMAJ ( Canadian Medical Association Journal ) ... looks at health and health care in Canada,s north ... includes Alaska in the US, Norway, Sweden, Finland, Russia, ...
... was diagnosed in 2007 with acute multiple myeloma, a form ... troubles all those who receive an upsetting diagnosis. The way ... however, was different. Barrager drew upon his engineering and management ... is sharing his insights with hospitals and doctors in his ...
... Reporter , MONDAY, Nov. 1 (HealthDay News) -- Pain is a ... reports of pain increasing during the final few months, a new ... being "troubled" by moderate or severe pain two years before they ... had jumped to nearly half. "This study shows that ...
... , MONDAY, Nov. 1 (HealthDay News) -- The success ... fat (MUFA), which are commonly found in nuts, seeds, avocados, ... oil, new research suggests. In the study, researchers randomly ... moderate elevated cholesterol levels to either a high-MUFA diet or ...
... , MONDAY, Nov. 1 (HealthDay News) -- Stroke ... the hospital on the weekend instead of a weekday, regardless ... Canadian researchers analyzed data from almost 21,000 stroke patients ... Only patients with their first stroke were included in the ...
... National Jewish Health has received a US patent for ... help assure many patients that dramatic changes in lifestyle ... PhD, Medical Director of the Advanced Diagnostic Laboratories at ... Donald MacGlashan, Jr. developed the diagnostic assay, which makes ...
Cached Medicine News:Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 2Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 3Health News:Almost Half of Elderly Report Pain in Life's Final Months 2Health News:Almost Half of Elderly Report Pain in Life's Final Months 3Health News:Adding Monounsaturated Fats to Diet May Boost Heart Health 2Health News:Weekend Admissions Worse for Stroke Victims: Study 2Health News:National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria 2
Sterile perfluorocarbon for intraocular Application....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
... hard contact lens cleaning solution ... use, and professionally proven cleaner. ... detergents resulting in a very ... deposits, cosmetic residue, salts, mucous ...
4.625 inches, curved blade 4 mm....
Medicine Products: